Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
Bristol-Myers Squibb Company logo

NASDAQ · BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

$64.19

Up+$2.48 (+4.02%)

Updated Nov 5, 2026, 5:03 AM

SID Score

6.4/10

Composite research score

Smart Money

62/100

Neutral

Market cap
104.23B
P/E ratio
17.28
Dividend yield
3.86%
52-week range
$53.44 – $68.64
Volume
14.13M
Avg. volume
16.54M

Price performance · BMY

BMY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

BMY closed at $64.19 after 21 trading sessions, up 7.52% for the selected period.

Last close
$64.19
Period change
+7.52%
Period low
$56.67
Period high
$64.19
Daily close
View OHLC price history
BMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$63.19$64.24$62.26$64.1914.13M
Nov 3, 2026$63.02$63.26$61.54$61.7110.29M
Nov 2, 2026$62.45$63.14$62.17$63.0210.84M
Oct 30, 2026$63.00$64.05$62.285$62.4812.67M
Oct 29, 2026$61.00$61.56$60.00$61.3914.77M
Oct 28, 2026$60.50$61.34$60.33$60.577.41M
Oct 27, 2026$61.21$61.64$60.92$61.557.78M
Oct 26, 2026$61.39$62.06$61.1145$61.617.84M
Oct 23, 2026$62.66$62.84$61.31$61.489.76M
Oct 22, 2026$61.46$63.59$61.04$63.0015.17M
Oct 21, 2026$61.50$61.8094$60.685$61.129.02M
Oct 20, 2026$59.93$61.815$59.83$61.6811.91M
Oct 19, 2026$59.40$59.8732$58.435$58.8311.55M
Oct 16, 2026$61.10$61.4273$59.54$59.7513.77M
Oct 15, 2026$60.67$62.25$60.39$60.5713.75M
Oct 14, 2026$56.81$59.385$56.58$59.2814.05M
Oct 13, 2026$57.775$58.0242$56.15$56.6716.96M
Oct 12, 2026$60.11$60.68$56.72$57.5822.57M
Oct 9, 2026$58.88$59.79$58.74$59.129.25M
Oct 8, 2026$59.10$59.94$58.73$59.5813.07M
Oct 7, 2026$59.45$60.10$59.01$59.7011.09M

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

Stock researchCompany · Overview

BMY research

Overview

Company profile and research snapshot.

Company profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.25
Implied upside
—
Analysts
17
BMY recent ratings
DateFirmRatingTarget
Oct 30, 2026Morgan StanleyUnderweight—
Oct 26, 2026Piper SandlerOverweight—
Oct 13, 2026Wells FargoEqual-Weight—
Oct 8, 2026Cantor FitzgeraldNeutral—
Oct 7, 2026Morgan StanleyUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 31, 2026

Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer Data

Bristol-Myers Squibb (NYSE:BMY) and BioNTech reported positive Phase 2 data for pumitamig in metastatic non-small cell lung cancer. The bispecific immunomodulator pumitamig, targeting PD-L1 and VEGF-A, showed strong antitumor activity with a manageable safety profile. This first global data set covers difficult lung cancer subgroups and informs further development plans for pumitamig. The new pumitamig Phase 2 readout fits into a wider picture for Bristol Myers Squibb that recent research...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By